This educational program will provide an overview of the current treatment landscape for generalized myasthenia gravis (gMG) and discuss the clinical evidence supporting the use an approved treatment option, IMAAVY® (Nipocalimab). The American Neurological Association (ANA) does not endorse the product(s) and/or service(s) advertised or for the company that advertises, manufactures, distributes, or promotes the […] Read More
This 1-hour session is designed to meet the educational needs of neuromuscular specialists, neurologists, and specialty NPs/PAs. It aims to increase target HCPs’ ability to: apply assessment of clinical features, diagnostic criteria, and disease burden to inform gMG management; integrate clinical efficacy and safety data for novel B-cell targeted therapies to inform treatment plans for […] Read More
Blood-based biomarkers are transforming the diagnosis and management of Alzheimer’s disease by offering a non-invasive, accessible, and cost-effective alternative to traditional diagnostic methods. This session will highlight the latest advancements in blood test research, pairing it with real-world experience from clinicians now using these tests in their own practices. Faculty will explore what is working […] Read More